Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".

Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ.

Cancer Lett. 2018 May 28;422:132. doi: 10.1016/j.canlet.2018.03.019. No abstract available.

PMID:
29579439
2.

A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.

Liu SH, Gu Y, Pascual B, Yan Z, Hallin M, Zhang C, Fan C, Wang W, Lam J, Spilker ME, Yafawi R, Blasi E, Simmons B, Huser N, Ho WH, Lindquist K, Tran TT, Kudaravalli J, Ma JT, Jimenez G, Barman I, Brown C, Chin SM, Costa MJ, Shelton D, Smeal T, Fantin VR, Pernasetti F.

Blood Adv. 2017 Jun 21;1(15):1088-1100. doi: 10.1182/bloodadvances.2016003921. eCollection 2017 Jun 27.

3.

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.

4.

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.

Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE.

J Hematol Oncol. 2017 May 19;10(1):112. doi: 10.1186/s13045-017-0435-x.

5.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

6.

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC.

J Med Chem. 2016 Mar 10;59(5):2005-24. doi: 10.1021/acs.jmedchem.5b01633. Epub 2016 Jan 28.

PMID:
26756222
7.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA.

N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23.

8.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

9.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T.

Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015 Jul 2.

10.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. doi: 10.1073/pnas.1420785112. Epub 2015 Mar 2.

11.

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.

Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P.

Drug Metab Dispos. 2015 Jan;43(1):54-62. doi: 10.1124/dmd.114.061143. Epub 2014 Oct 27.

PMID:
25349124
12.

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P.

J Pharmacol Exp Ther. 2014 Oct;351(1):67-76. doi: 10.1124/jpet.114.217141. Epub 2014 Jul 29.

PMID:
25073473
13.

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Huang Q, Kania RS, Kath JC, Lam H, Lam JL, Le PT, Lingardo L, Liu W, McTigue M, Palmer CL, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski S, Zhu H, Zhu J, Zou HY, Edwards MP.

J Med Chem. 2014 Jun 12;57(11):4720-44. doi: 10.1021/jm500261q. Epub 2014 Jun 3.

PMID:
24819116
14.

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook AS, Cui JJ, Dack KN, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Johnson PS, Kania RS, Lam H, Lam JL, Le PT, Li Q, Lingardo L, Liu W, Lu MW, McTigue M, Palmer CL, Richardson PF, Sach NW, Shen H, Smeal T, Smith GL, Stewart AE, Timofeevski S, Tsaparikos K, Wang H, Zhu H, Zhu J, Zou HY, Edwards MP.

J Med Chem. 2014 Feb 27;57(4):1170-87. doi: 10.1021/jm401805h. Epub 2014 Feb 6.

15.

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.

Walls M, Baxi SM, Mehta PP, Liu KK, Zhu J, Estrella H, Li C, Zientek M, Zong Q, Smeal T, Yin MJ.

Clin Cancer Res. 2014 Feb 1;20(3):631-43. doi: 10.1158/1078-0432.CCR-13-1663. Epub 2013 Nov 15. Retraction in: Clin Cancer Res. 2017 Aug 1;23 (15):4523.

16.

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.

Baxi SM, Tan W, Murphy ST, Smeal T, Yin MJ.

PLoS One. 2012;7(10):e48402. doi: 10.1371/journal.pone.0048402. Epub 2012 Oct 31. Retraction in: PLoS One. 2017 Apr 10;12 (4):e0175772.

17.

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.

Bagrodia S, Smeal T, Abraham RT.

Pigment Cell Melanoma Res. 2012 Nov;25(6):819-31. doi: 10.1111/pcmr.12007. Epub 2012 Sep 14. Review.

PMID:
22883054
18.

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.

Clin Cancer Res. 2012 Sep 15;18(18):5008-19. doi: 10.1158/1078-0432.CCR-12-1379. Epub 2012 Jul 17.

19.

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.

Torti VR, Wojciechowicz D, Hu W, John-Baptiste A, Evering W, Troche G, Marroquin LD, Smeal T, Yamazaki S, Palmer CL, Burns-Naas LA, Bagrodia S.

Mol Cancer Ther. 2012 Oct;11(10):2274-83. doi: 10.1158/1535-7163.MCT-11-0984. Epub 2012 Jul 2.

20.

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.

Guo C, McAlpine I, Zhang J, Knighton DD, Kephart S, Johnson MC, Li H, Bouzida D, Yang A, Dong L, Marakovits J, Tikhe J, Richardson P, Guo LC, Kania R, Edwards MP, Kraynov E, Christensen J, Piraino J, Lee J, Dagostino E, Del-Carmen C, Deng YL, Smeal T, Murray BW.

J Med Chem. 2012 May 24;55(10):4728-39. doi: 10.1021/jm300204j. Epub 2012 May 14.

PMID:
22554206
21.

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.

Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, Engstrom LD, Yamazaki S, Parker M, Timofeevski S, Cui JJ, McTigue M, Los G, Bender SL, Smeal T, Christensen JG.

Mol Cancer Ther. 2012 Apr;11(4):1036-47. doi: 10.1158/1535-7163.MCT-11-0839. Epub 2012 Mar 2.

22.

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.

Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ.

Cancer Lett. 2011 Jan 1;300(1):30-9. doi: 10.1016/j.canlet.2010.09.002. Retraction in: Cancer Lett. 2018 May 28;422:132.

PMID:
20926183
23.

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.

Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T.

Mol Cancer Ther. 2010 Jun;9(6):1618-28. doi: 10.1158/1535-7163.MCT-10-0034. Epub 2010 Jun 8.

24.

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist S, Smeal T.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. doi: 10.1073/pnas.0911863107. Epub 2010 May 3.

25.

Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target.

Nassirpour R, Shao L, Flanagan P, Abrams T, Jallal B, Smeal T, Yin MJ.

Mol Cancer Res. 2010 May;8(5):717-28. doi: 10.1158/1541-7786.MCR-09-0291. Epub 2010 Apr 20. Retraction in: Mol Cancer Res. 2017 Mar;15(3):358.

26.

Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.

Kung PP, Funk L, Meng J, Collins M, Zhou JZ, Johnson MC, Ekker A, Wang J, Mehta P, Yin MJ, Rodgers C, Davies JF 2nd, Bayman E, Smeal T, Maegley KA, Gehring MR.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6273-8. doi: 10.1016/j.bmcl.2008.09.081. Epub 2008 Sep 26.

PMID:
18929486
27.

PAK4 mediates morphological changes through the regulation of GEF-H1.

Callow MG, Zozulya S, Gishizky ML, Jallal B, Smeal T.

J Cell Sci. 2005 May 1;118(Pt 9):1861-72. Epub 2005 Apr 12.

28.

The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis.

Yin MJ, Shao L, Voehringer D, Smeal T, Jallal B.

J Biol Chem. 2003 Dec 26;278(52):52454-60. Epub 2003 Oct 16.

29.

Malignant wound management: what dressings do nurses use?

Wilkes L, White K, Smeal T, Beale B.

J Wound Care. 2001 Mar;10(3):65-9. Erratum in: J Wound Care. 2002 Apr;10(4):122.

PMID:
11924353
30.

Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines.

Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, Jallal B, Smeal T.

J Biol Chem. 2002 Jan 4;277(1):550-8. Epub 2001 Oct 19.

31.

An ongoing challenge. Providing palliative care nursing in the community.

White K, Davies M, Smeal T.

Lamp. 1997 Jun;54(5):15, 17. No abstract available.

PMID:
9335753
32.

Mechanisms of cellular senescence.

Smeal T, Guarente L.

Curr Opin Genet Dev. 1997 Apr;7(2):281-7. Review.

PMID:
9115418
33.

Loss of transcriptional silencing causes sterility in old mother cells of S. cerevisiae.

Smeal T, Claus J, Kennedy B, Cole F, Guarente L.

Cell. 1996 Feb 23;84(4):633-42.

35.

c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases.

Minden A, Lin A, Smeal T, Dérijard B, Cobb M, Davis R, Karin M.

Mol Cell Biol. 1994 Oct;14(10):6683-8.

36.

Activation of cAMP and mitogen responsive genes relies on a common nuclear factor.

Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J, Montminy M.

Nature. 1994 Jul 21;370(6486):226-9.

PMID:
8028671
37.
38.

Control of AP-1 activity by signal transduction cascades.

Lin A, Smeal T, Binetruy B, Deng T, Chambard JC, Karin M.

Adv Second Messenger Phosphoprotein Res. 1993;28:255-60. Review. No abstract available.

PMID:
8398411
39.

The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases.

Devary Y, Gottlieb RA, Smeal T, Karin M.

Cell. 1992 Dec 24;71(7):1081-91.

PMID:
1473146
40.

Control of transcription factors by signal transduction pathways: the beginning of the end.

Karin M, Smeal T.

Trends Biochem Sci. 1992 Oct;17(10):418-22. Review.

PMID:
1455510
41.

Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity.

Lin A, Frost J, Deng T, Smeal T, al-Alawi N, Kikkawa U, Hunter T, Brenner D, Karin M.

Cell. 1992 Sep 4;70(5):777-89. Erratum in: Cell. 1992 Nov 27;71(5):887.

PMID:
1516134
42.

Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73.

Smeal T, Binetruy B, Mercola D, Grover-Bardwick A, Heidecker G, Rapp UR, Karin M.

Mol Cell Biol. 1992 Aug;12(8):3507-13.

43.

Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.

Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M.

Nature. 1991 Dec 12;354(6353):494-6.

PMID:
1749429
44.

Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain.

Binétruy B, Smeal T, Karin M.

Nature. 1991 May 9;351(6322):122-7.

PMID:
1903181
45.

Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.

Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T.

Cell. 1991 Feb 8;64(3):573-84.

PMID:
1846781
46.

Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M.

Cell. 1990 Sep 21;62(6):1205-15.

PMID:
2169352
47.

DNA-binding activity of Jun is increased through its interaction with Fos.

Allegretto EA, Smeal T, Angel P, Spiegelman BM, Karin M.

J Cell Biochem. 1990 Apr;42(4):193-206.

PMID:
2111328
48.

Different requirements for formation of Jun: Jun and Jun: Fos complexes.

Smeal T, Angel P, Meek J, Karin M.

Genes Dev. 1989 Dec;3(12B):2091-100.

49.
50.

The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1.

Angel P, Hattori K, Smeal T, Karin M.

Cell. 1988 Dec 2;55(5):875-85.

PMID:
3142689

Supplemental Content

Support Center